![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
February 10, 2023
Plans for the year ahead; a focus on data; the future of cancer screening studies
April 15, 2022
Enrollment doubles in past 17 months due to specific efforts — Black participation rises above 20%
July 7, 2021
Recent ECOG-ACRIN trial updates and results
May 28, 2021
Virtual Spring 2021 Group Meeting generates record attendance; screening and genomic trials return to full activity
February 25, 2021
COVID-19 vaccination and patients with cancer; the impact of delayed screening; a virtual Spring 2021 Group Meeting
October 19, 2020
October accrual is on pace to be the highest month on record. Since July 1, TMIST has enrolled more patients than all other National Cancer Institute clinical trials combined. An unheard-of number (nearly 20%) are Black and African American women. Drs. Etta Pisano and Mitch Schnall provide the latest status of the trial and discuss its continuing relevance
June 10, 2020
TMIST will provide data that is critical for relating the increased rate of detection of early breast cancers to the clinical outcomes of the screening population
February 28, 2020
January meeting with NCI leaders and the Cooperative Group Chairs; Congress increases NCI and overall NIH budget for FY 2020; EA opens two new trials, one for pancreatic cyst monitoring (EA2185) and the other to evaluate nivolumab in head and neck cancer (EA3161); plans are underway for the next Comis Symposium
January 14, 2020
Reflecting on key milestones in 2019: TMIST breast cancer screening trial continues to ramp up; NCORP grant renewal emphasizes screening, symptom control, and cancer care delivery research; new role for Dr. Al Benson; E1912's practice-changing trial results; update on Dr. Otis Brawley's efforts to form the Social Determinants of Health Working Group; EA launches the Comis Symposium